We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Efficacy of a Propolis-Based Syrup (FARINGEL) in Preventing Radiation-Induced Esophagitis in Locally Advanced Lung Cancer.
- Authors
Ippolito, Edy; Floreno, Barnaba; Rinaldi, Carla Germana; Trodella, Lucio; Meroni, Federica Loretta; Iurato, Aurelia; D’Angelillo, Rolando Maria; Ramella, Sara; Fiore, Michele
- Abstract
<bold><italic>Aim:</italic></bold> To evaluate the efficacy of a propolis-based syrup, FARINGEL®, in preventing radiation-induced esophagitis in locally advanced lung cancer patients. Methods. Patients were treated with concurrent chemoradiotherapy (CRT) using involved-field radiotherapy (RT). Every patient received FARINGEL at the beginning of CRT until the first follow-up. The data of the study group were compared with the data of a control group treated without the administration of the syrup. <bold><italic>Results:</italic></bold> Forty-five patients were enrolled. Forty-one (91.1%) completed the protocol and were evaluable for esophagitis. Grade ≥2 toxicity occurred in 9/41 patients (22%). No differences in overall toxicity were detected between the study group and the control group (<italic>n</italic> = 55, 60.9 vs. 54.5%; <italic>p</italic> = ns). Grade 2–3 esophagitis was lower in the study group in comparison with the control group (22 and 38%, respectively), but statistical significance was not reached (<italic>p</italic> = 0.09). However, the onset of grade ≥2 esophagitis was delayed in the study group compared to the control group, occurring at higher doses of RT (41.8 vs. 25.4 Gy; <italic>p</italic> < 0.001). Furthermore, the mean number of interruption days for esophagitis was lower in the study group than in the control group (0.6 ± 2.0 vs. 2.1 ± 3.6; <italic>p</italic> = 0.025). <bold><italic>Conclusion:</italic></bold> FARINGEL was well-tolerated and delayed esophagitis that was induced by CRT for locally advanced lung cancer.
- Subjects
CHEMORADIOTHERAPY; LUNG cancer; PROPOLIS; RADIOTHERAPY; CANCER patients
- Publication
Chemotherapy (0009-3157), 2018, Vol 63, Issue 2, p76
- ISSN
0009-3157
- Publication type
Article
- DOI
10.1159/000487897